blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3487859

EP3487859 - ANTIMETASTATIC 2H-SELENOPHENO[3,2-H]CHROMENES, SYNTHESIS THEREOF, AND METHODS OF USING SAME AGENTS [Right-click to bookmark this link]
Former [2019/22]ANTIMETASTATIC 2H-SELENOPHENO[3,2-h]CHROMENES, SYNTHESIS THEREOF, AND METHODS OF USING SAME AGENTS
[2020/11]
StatusNo opposition filed within time limit
Status updated on  26.11.2021
Database last updated on 19.07.2024
FormerThe patent has been granted
Status updated on  18.12.2020
FormerGrant of patent is intended
Status updated on  29.07.2020
FormerRequest for examination was made
Status updated on  07.07.2020
FormerGrant of patent is intended
Status updated on  25.02.2020
FormerRequest for examination was made
Status updated on  26.04.2019
FormerThe international publication has been made
Status updated on  26.01.2018
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024  [2024/29]
Applicant(s)For all designated states
Latvian Institute Of Organic Synthesis
Aizkraukles Street 21
1006 Riga / LV
[2019/22]
Inventor(s)01 / ARSENJANS, Pavels
Vangazu Street 30-45
LV-1024 Riga / LV
02 / VASILJEVA, Jelena
Ilukstes 54/6-68
LV-1082 Riga / LV
03 / DOMRACHEVA, Ilona
Maskavas Street 303-86
LV-1063 Riga / LV
04 / SHESTAKOVA, Irina
Spilves street 7-37
LV-1005 Riga / LV
05 / KALVINS, Ivars
Libiesu Street 25
LV-5052 Ikskile / LV
 [2019/22]
Representative(s)Ruschke, Hans Edvard
Ruschke Madgwick Seide & Kollegen
Patentanwälte Patent Attorney (UK) PartG mbB
Postfach 86 06 29
81633 München / DE
[2021/03]
Former [2019/22]Ruschke, Hans Edvard
Ruschke Madgwick Seide & Kollegen
Postfach 86 06 29
81633 München / DE
Application number, filing date16745850.421.07.2016
[2019/22]
WO2016IB54341
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018015788
Date:25.01.2018
Language:EN
[2018/04]
Type: A1 Application with search report 
No.:EP3487859
Date:29.05.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 25.01.2018 takes the place of the publication of the European patent application.
[2019/22]
Type: B1 Patent specification 
No.:EP3487859
Date:20.01.2021
Language:EN
[2021/03]
Search report(s)International search report - published on:EP25.01.2018
ClassificationIPC:C07D517/04, A61K31/559, A61P35/00
[2019/22]
CPC:
C07D517/04 (EP,EA,US); A61K33/04 (US); A61P35/00 (EP);
A61P35/04 (EP); A61P43/00 (EP); C07D517/14 (US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/22]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:ANTIMETASTATISCHE 2H-SELENOPHENO[3,2-H]CHROMENE, SYNTHESE DARAUS UND VERFAHREN ZUR VERWENDUNG DIESER MITTEL[2019/22]
English:ANTIMETASTATIC 2H-SELENOPHENO[3,2-H]CHROMENES, SYNTHESIS THEREOF, AND METHODS OF USING SAME AGENTS[2020/11]
French:2H-SÉLÉNOPHÉNO [3,2-H]CHROMÈNES ANTIMÉTASTATIQUES, LEURS SYNTHÈSES ET LEURS PROCÉDÉS D'UTILISATION[2020/11]
Former [2019/22]ANTIMETASTATIC 2H-SELENOPHENO[3,2-h]CHROMENES, SYNTHESIS THEREOF, AND METHODS OF USING SAME AGENTS
Former [2019/22]SYNTHÈSE DES 2H-SÉLÉNOPHÉNO [3,2-H]CHROMÈNES ANTIMÉTASTATIQUES, ET LES PROCÉDÉS D'UTILISATION DES AGENTS SIMILAIRES
Entry into regional phase12.02.2019National basic fee paid 
12.02.2019Designation fee(s) paid 
12.02.2019Examination fee paid 
Examination procedure12.02.2019Examination requested  [2019/22]
12.02.2019Date on which the examining division has become responsible
09.09.2019Amendment by applicant (claims and/or description)
26.02.2020Communication of intention to grant the patent
03.07.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
30.07.2020Communication of intention to grant the patent
01.12.2020Fee for grant paid
01.12.2020Fee for publishing/printing paid
04.12.2020Receipt of the translation of the claim(s)
Opposition(s)21.10.2021No opposition filed within time limit [2021/52]
Fees paidRenewal fee
12.02.2019Renewal fee patent year 03
19.07.2019Renewal fee patent year 04
16.07.2020Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU21.07.2016
AL20.01.2021
CY20.01.2021
CZ20.01.2021
EE20.01.2021
FI20.01.2021
HR20.01.2021
LT20.01.2021
LV20.01.2021
MC20.01.2021
MK20.01.2021
RO20.01.2021
RS20.01.2021
SI20.01.2021
SK20.01.2021
SM20.01.2021
TR20.01.2021
BG20.04.2021
GR21.04.2021
IS20.05.2021
PT20.05.2021
LU21.07.2021
[2024/29]
Former [2024/22]HU21.07.2016
AL20.01.2021
CY20.01.2021
CZ20.01.2021
EE20.01.2021
FI20.01.2021
HR20.01.2021
LT20.01.2021
LV20.01.2021
MC20.01.2021
MK20.01.2021
RO20.01.2021
RS20.01.2021
SI20.01.2021
SK20.01.2021
SM20.01.2021
BG20.04.2021
GR21.04.2021
IS20.05.2021
PT20.05.2021
LU21.07.2021
Former [2023/33]HU21.07.2016
AL20.01.2021
CY20.01.2021
CZ20.01.2021
EE20.01.2021
FI20.01.2021
HR20.01.2021
LT20.01.2021
LV20.01.2021
MC20.01.2021
RO20.01.2021
RS20.01.2021
SI20.01.2021
SK20.01.2021
SM20.01.2021
BG20.04.2021
GR21.04.2021
IS20.05.2021
PT20.05.2021
LU21.07.2021
Former [2023/30]AL20.01.2021
CY20.01.2021
CZ20.01.2021
EE20.01.2021
FI20.01.2021
HR20.01.2021
LT20.01.2021
LV20.01.2021
MC20.01.2021
RO20.01.2021
RS20.01.2021
SI20.01.2021
SK20.01.2021
SM20.01.2021
BG20.04.2021
GR21.04.2021
IS20.05.2021
PT20.05.2021
LU21.07.2021
Former [2022/23]AL20.01.2021
CZ20.01.2021
EE20.01.2021
FI20.01.2021
HR20.01.2021
LT20.01.2021
LV20.01.2021
MC20.01.2021
RO20.01.2021
RS20.01.2021
SI20.01.2021
SK20.01.2021
SM20.01.2021
BG20.04.2021
GR21.04.2021
IS20.05.2021
PT20.05.2021
LU21.07.2021
Former [2022/18]AL20.01.2021
CZ20.01.2021
EE20.01.2021
FI20.01.2021
HR20.01.2021
LT20.01.2021
LV20.01.2021
MC20.01.2021
RO20.01.2021
RS20.01.2021
SI20.01.2021
SK20.01.2021
SM20.01.2021
BG20.04.2021
GR21.04.2021
PT20.05.2021
Former [2022/13]AL20.01.2021
CZ20.01.2021
EE20.01.2021
FI20.01.2021
HR20.01.2021
LT20.01.2021
LV20.01.2021
RO20.01.2021
RS20.01.2021
SI20.01.2021
SK20.01.2021
SM20.01.2021
BG20.04.2021
GR21.04.2021
PT20.05.2021
Former [2022/10]AL20.01.2021
CZ20.01.2021
EE20.01.2021
FI20.01.2021
HR20.01.2021
LT20.01.2021
LV20.01.2021
RO20.01.2021
RS20.01.2021
SK20.01.2021
SM20.01.2021
BG20.04.2021
GR21.04.2021
PT20.05.2021
Former [2022/07]AL20.01.2021
CZ20.01.2021
EE20.01.2021
FI20.01.2021
HR20.01.2021
LT20.01.2021
LV20.01.2021
RO20.01.2021
RS20.01.2021
SK20.01.2021
SM20.01.2021
BG20.04.2021
GR21.04.2021
IS20.05.2021
PT20.05.2021
Former [2021/50]CZ20.01.2021
EE20.01.2021
FI20.01.2021
HR20.01.2021
LT20.01.2021
LV20.01.2021
RO20.01.2021
RS20.01.2021
SK20.01.2021
SM20.01.2021
BG20.04.2021
GR21.04.2021
IS20.05.2021
PT20.05.2021
Former [2021/48]CZ20.01.2021
EE20.01.2021
FI20.01.2021
HR20.01.2021
LT20.01.2021
LV20.01.2021
RS20.01.2021
SM20.01.2021
BG20.04.2021
GR21.04.2021
IS20.05.2021
PT20.05.2021
Former [2021/46]FI20.01.2021
HR20.01.2021
LT20.01.2021
LV20.01.2021
RS20.01.2021
SM20.01.2021
BG20.04.2021
GR21.04.2021
IS20.05.2021
PT20.05.2021
Former [2021/42]FI20.01.2021
HR20.01.2021
LT20.01.2021
LV20.01.2021
RS20.01.2021
BG20.04.2021
GR21.04.2021
IS20.05.2021
PT20.05.2021
Former [2021/37]FI20.01.2021
HR20.01.2021
LT20.01.2021
LV20.01.2021
RS20.01.2021
BG20.04.2021
GR21.04.2021
PT20.05.2021
Former [2021/36]FI20.01.2021
HR20.01.2021
LT20.01.2021
BG20.04.2021
GR21.04.2021
PT20.05.2021
Former [2021/35]FI20.01.2021
HR20.01.2021
LT20.01.2021
PT20.05.2021
Former [2021/33]FI20.01.2021
LT20.01.2021
PT20.05.2021
Cited inInternational search[A]  - PAVEL ARSENYAN ET AL, "Selenopheno[3,2-c]- and [2,3-c]coumarins: Synthesis, cytotoxicity, angiogenesis inhibition, and antioxidant properties", COMPTES RENDUS - CHIMIE., FR, (20150401), vol. 18, no. 4, doi:10.1016/j.crci.2014.09.007, ISSN 1631-0748, pages 399 - 409, XP055297375 [A] 1-11 * compounds 11-18 *

DOI:   http://dx.doi.org/10.1016/j.crci.2014.09.007
 [A]  - P. ARSENYAN ET AL, "Synthesis and molecular structure of the methyl ester of 3-bromo-2-(2-hydroxy-2-propyl)-7-oxo-7H-selenolo[2,3-f]chromene-8-carboxylic acid", CHEMISTRY OF HETEROCYCLIC COMPOUNDS, US, (20110501), vol. 47, no. 2, doi:10.1007/s10593-011-0746-8, ISSN 0009-3122, pages 237 - 241, XP055297366 [A] 1-11 * compound 4 *

DOI:   http://dx.doi.org/10.1007/s10593-011-0746-8
by applicant   - HUNTER ET AL., BREAST CANCER RES, (2008), vol. 10, page S2
    - TALMADGE ET AL., CANCER RES, (2010), vol. 70, pages 5649 - 5669
    - ESSNER ET AL., ARCH SURG, (2004), vol. 139, pages 961 - 966,966-7
    - ACHEN; STACKER, Annals of the New York Academy of Sciences, (2008), vol. 1131, pages 225 - 234
    - LI; LI, INT. J. ONCOL., (2014), vol. 44, pages 1806 - 1812
    - FIZAZI K; GRECO FA; PAVLIDIS N; DAUGAARD G; OIEN K; PENTHEROUDAKIS G ET AL., "Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", ANN ONCOL., (201509), vol. 26, no. 5, pages 133 - 8
    - VAJDIC CM; GOLDSTEIN D, "Cancer of unknown primary site", AUST FAM PHYSICIAN, (20150904), vol. 4, no. 9, pages 640 - 3
    - POSTE ET AL., CANCER RES., (1980), vol. 40, pages 1636 - 1644
    - ASLAKSON; MILLER, CANCER RES, (1992), vol. 52, pages 1399 - 1405
    - ECKHARDT ET AL., NAT REV. DRUG DISCOV., (2012), vol. 11, pages 479 - 497
    - KHANNA ET AL., CARCINOGENESIS, (2005), vol. 26, pages 513 - 523
    - ASLAKSON, CANCER RES, (1992), vol. 52, pages 1399 - 1405
    - LEWIS ET AL., CANCER RES, (2005), page 65
    - HEPPNER ET AL., BREAST CANCER RES, (2000), vol. 2, pages 331 - 334
    - JOHNSON ET AL., INT. J. CELL CLONING, (1985), vol. 3, pages 91 - 105
    - SERAFINI ET AL., CANCER IMMUNOL. IMMUNOTHER., (2004), vol. 53, pages 64 - 72
    - DU PRE ET AL., EXPERIM. MOL. PATHOL., (2007), vol. 82, pages 12 - 24
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.